2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
8
Tumor-Agnostic
3
Breast
3
Thoracic
2
Genitourinary
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Radiotherapy
221
Cyclophosphamide
211
Doxorubicin
210
Temozolomide
182
Ifosfamide
121
Filgrastim
111
Imatinib Mesylate
104
Etoposide
101
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Magnetic Resonance Spectroscopy
81
Irinotecan
79
pembrolizumab
75
Radiation
70
Carboplatin
65
Methotrexate
62
pazopanib
61
Nivolumab
58
Cisplatin
58
fludarabine phosphate
57
Surgical Procedures, Operative
57
Peripheral Blood Stem Cell Transplantation
57
Specimen Handling
56
Trabectedin
52
Docetaxel
50
Biopsy
50
Busulfan
49
Melphalan
46
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Poly(ADP-ribose) Polymerase Inhibitors
×
Sarcoma
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled